Prasugrel
Indication
with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) (NICE TA317)
NICE TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)
MHRA Drug Safety Update - Prasugrel: rare but serious hypersensitivity reactions
Amber level 0
Brand:
Nice TA:
317
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Cardiovascular system
Background
NICE technology appraisal guidance 317 replaces NICE technology appraisal guidance 182 issued in October 2009. Prasugrel (Efient®)10 mg in combination with aspirin is recommended as an option within its marketing authorisation, that is, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina [UA], non-ST segment elevation myocardial infarction [NSTEMI] or ST segment elevation myocardial infarction [STEMI]) having primary or delayed percutaneous coronary intervention. The updated recommendations for prasugrel with percutaneous coronary intervention for treating acute coronary syndromes include people with high-risk NSTEMI and unstable angina who do not have diaetes mellitus.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: